Clinical Trials Logo

Clinical Trial Summary

The projects investigate if treatment with isocapnic hyperventilation can eliminate methanol from the body in a similar manner to dialysis. This is achieved by administering the antidote (fomepizole) and let the patient breathe on a isocapnic hyperventilation device while samples of blood, urine and maybe the breath are collected to measure the contents of methanol and its metabolites.


Clinical Trial Description

Isocapnic hyperventilation (iHV) The normal physiology breathing is a careful balance between the number of breaths per minute (rate/min) and the depth of each breath (tidal volume, Vt). Together they make up the minute ventilation (MV), where MV= rate x Vt). To maintain stable homeostasis in the organism, the minute ventilation is closely regulated to maintain adequate uptake of oxygen and adequate elimination of the carbon dioxide (CO2) that is produced by the metabolism. Too low minute ventilation leads to a buildup of CO2 and decrease in blood pH (respiratory acidosis), while hyperventilation (too high minute ventilation) leads to an excess loss of CO2 and increase in blood pH (respiratory alkalosis). The same mechanism will also enable the organism to compensate any metabolic disturbances (up to a certain point): A metabolic acidosis will be counteracted by a hyperventilation, whereas a metabolic alkalosis will be counteracted by a hypoventilation, both with the ultimate goal of keeping the acidity (as given by the pH) as closely regulated as possible. The concept of isocapnic hyperventilation (iHV) allows the person to hyperventilate while keeping the CO2 within normal limits at the same time. The ClearMate (Thornhill Research Inc., Canada) adds CO2 to the inspired air to compensate to the increased loss induced by the increased minute ventilation. This means that hyperventilation can occur, and a wash-out of volatile substances such as methanol will happen without disrupting the important CO2 balance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06173817
Study type Interventional
Source Oslo University Hospital
Contact Knut Erik Hovda, MD, Ph D
Phone +4799618356
Email knuterikhovda@gmail.com
Status Recruiting
Phase Phase 2/Phase 3
Start date December 20, 2023
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Completed NCT04064801 - Red Cell Distribution Width as a Predictor of Mortality in Acute Methanol Poisoning
Completed NCT04877067 - Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation Phase 3